Embracing Change: How Innovators are Advancing Continuous Biopharma Manufacturing

June 12, 2019 8:00 AM - 10:00 AM

MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139

Building on the realization of continuous manufacturing for commercial small molecule APIs and drug products, the dominos finally are beginning to fall into place for the advancement of integrated processes for biopharmaceutical applications. Regulatory engagement, novel and disruptive process and measurement technologies, and simple economics all are playing key roles in recent progress. This forum, intended for a broad audience of scientists and business leaders across the MassBio community, will explore how each of these change-agents are helping to overcome long-time deterrents and, in doing so, have the potential for improving manufacturing reliability and product quality – thereby reducing risks to patients and other key stakeholders.

Discussion and Key Take-Aways Will Include:

  1. Establishing the business case for continuous biomanufacturing – when and for what applications does it make sense?
  2. Applying single-use technologies, automation, and other innovations to enable success in downstream continuous processing.
  3. Advances in measurement and process analytical technologies to enable process/product understanding in alignment with regulatory guidances.
Forum Bonus: We will have extended networking from 10am-11am so you can meet with Bio-Process Systems Alliance, BioPhorum and NIIMBL organizations to learn how they work with industry to accelerate manufacturing innovation as well as find out about their latest white papers, reports and events.
Founder, BioGuides LLC
Lynne is the founder of BioGuides which provides senior business development, technology de-risking, strategic and commercialization strategy services to early stage and established life sciences companies with innovative, emerging products, services and technologies. She has managed multiple start-up technologies and has held various corporate and business development, marketing and outsourced manufacturing roles throughout her career working for technology providers, CDMOs and biotechnology companies in biomanufacturing, drug development and cell therapy. Her most recent corporate role was Director of Continuous Bioprocessing, the Americas, for Pall Corporation after completing the asset sales of the BioSMB technology to Pall. She is also the co-executive director of the BioInnovation Group, a for public benefit corporation consisting of an elite group of senior industry professionals who provide guidance to technology companies on the adoption criteria and customer needs in Biopharmaceutical development and manufacturing.